Figure 6.

Peripheral Priming Enables Efficacious Loco-regional Therapy against Aggressive Brain Tumors

(A) C57BL/6 mice bearing CT2A-fLuc tumors were primed i.p. with 5 × 10⁸ VSVΔ51-GFP at 6 days post-tumor implantation (day 0) and treated IC with a single dose of 5 × 10⁷ VSVΔ51-NR 18 hr later (n = 23). Control mice received an intracranial infusion of PBS following a VSVΔ51-GFP prime (n = 9) or dual PBS prime/PBS treat (n = 9). (B) Survival curves for different treatment groups. *p < 0.05 (VSV prime/PBS treat versus VSV prime/VSV treat) and ***p < 0.0001 (PBS prime/PBS treat versus VSV prime/VSV treat) assessed by log-rank (Mantel-Cox) test.